The Contribution of Maternal HIV Seroconversion During Late Pregnancy and Breastfeeding to Mother-to-Child Transmission of HIV

Leigh F. Johnson, PhD,* Kathryn Stinson, MPH,* Marie-Louise Newell, MB, PhD,†‡ Ruth M. Bland, MD,†§ Harry Moultrie, MD, MSc,¶ Mary-Ann Davies, MD,* Thomas M. Rehle, MD, PhD,†# Rob E. Dorrington, MPhil,** and Gayle G. Sherman, MD, PhD††‡‡

Background: The prevention of mother-to-child transmission (PMTCT) of HIV has been focused mainly on women who are HIV positive at their first antenatal visit, but there is uncertainty regarding the contribution to overall transmission from mothers who seroconvert after their first antenatal visit and before weaning.

Method: A mathematical model was developed to simulate changes in mother-to-child transmission of HIV over time, in South Africa. The model allows for changes in infant feeding practices as infants age, temporal changes in the provision of antiretroviral prophylaxis and counseling on infant feeding, as well as temporal changes in maternal HIV prevalence and incidence.

Results: The proportion of mother-to-child transmission (MTCT) from mothers who seroconverted after their first antenatal visit was 26% [95% confidence interval (CI): 22% to 30%] in 2008, or 15,000 of 57,000 infections. It is estimated that by 2014, total MTCT will reduce to 39,000 per annum, and transmission from mothers seroconverting after their first antenatal visit will reduce to 13,000 per annum, accounting for 34% (95% CI: 29% to 39%) of MTCT. If maternal HIV incidence during late pregnancy and breastfeeding were reduced by 50% after 2010, and HIV screening were repeated in late pregnancy and at 6-week immunization visits after 2010, the average annual number of MTCT cases over the 2010–2015 period would reduce by 28% (95% CI: 25% to 31%), from 39,000 to 28,000 per annum.

Conclusion: Maternal seroconversion during late pregnancy and breastfeeding contributes significantly to the pediatric HIV burden and needs greater attention in the planning of prevention of MTCT programs.

Key Words: HIV/AIDS, mathematical model, South Africa, vertical transmission

(J Acquir Immune Defic Syndr 2012;59:417–425)

INTRODUCTION

In 2009, UNAIDS issued a call for the “virtual elimination” of mother-to-child transmission of HIV globally by 2015. This vision has stimulated increased investment in programs for the prevention of mother-to-child transmission (PMTCT) of HIV. However, the focus of most programs has been on pregnant women who are identified as HIV positive during antenatal care. The prevention of transmission from mothers who seroconvert after antenatal screening, in late pregnancy or while breastfeeding, is much more challenging. Acutely infected women are likely to be at a higher risk of transmitting HIV to their children than chronically infected women, partly because the high levels of HIV viral load that occur during acute infection are associated with increased risk of perinatal transmission and transmission through breastfeeding, and partly because the maternal immune response during acute infection may not be sufficiently mature to allow significant transfer of protective immunity to the child. These women are also more difficult to identify and are therefore less likely to receive timely antiretroviral prophylaxis and counseling on infant feeding.

Mathematical models of the sexual transmission of HIV have suggested that acute HIV infection could account for a significant proportion of sexual transmission during the early stages of the HIV epidemic and allowance for a high level of infectiousness during the first few months after HIV infection.
acquisition has thus become standard in modeling the sexual transmission of HIV. However, in modeling vertical transmission of HIV, only a handful of studies have considered maternal seroconversion after the first antenatal visit and the associated high transmission risk during the acute phase of infection.\textsuperscript{11–13} In the most recent of these studies,\textsuperscript{12} 43% of all vertical transmission in Botswana was estimated to be transmitted from mothers who seroconverted after their first antenatal screening visit and before cessation of breastfeeding. Further modeling work is required to assess the significance of transmission from recently infected mothers in other settings, and to assess the potential impact of interventions to reduce this transmission.

The significance of transmission from recently infected mothers is likely to depend crucially on factors such as the HIV epidemic stage, the extent of PMTCT programs, infant feeding practices and the timing of maternal HIV testing in pregnancy. This article describes a dynamic model that has been developed to assess the effect of these factors. The model has been parameterized using data from South Africa, a country in which PMTCT has been scaled up rapidly over the last decade, where HIV incidence remains high and breastfeeding is common. Our objective is to assess the extent to which recently infected mothers contribute to total vertical transmission at different stages in the South African epidemic, and to assess the potential impact of programs to limit this transmission.

**METHODS**

The structure of the model is illustrated in Figure 1. Annual numbers of births to women who are HIV seronegative at their first antenatal visit, and annual numbers of births to women who are HIV seropositive at their first antenatal visit, are both estimated from the ASSA2003 AIDS and Demographic model, a model of the South African HIV epidemic that is calibrated to HIV prevalence data collected at first antenatal visits.\textsuperscript{14,15} This model is also used to estimate annual HIV incidence rates in pregnant women, and the annual incidence rates and numbers of births are shown in an online appendix (see Section 1, Supplemental Digital Content 1, http://links.lww.com/QAI/A241). The first antenatal visit is assumed to occur at 23-week gestation\textsuperscript{16–18} and delivery at 39 weeks,\textsuperscript{16} on average, so that the average time in which a woman seronegative at her first visit can acquire HIV before delivery is 20 weeks if a 4-week window period is assumed.\textsuperscript{19} The probability that a pregnant woman seronegative at her first antenatal visit acquires HIV before delivery is therefore calculated as the annual HIV incidence rate in pregnant women multiplied by a factor of 0.38 (20/52). The assumed probability that a woman who acquires HIV in late pregnancy transmits HIV perinatally is based on a review of studies conducted in settings where breastfeeding is rare (summarized in Table 1) and on perinatal transmission rates from HIV positive South African mothers who reported previously testing negative.\textsuperscript{12,33}

Assumptions regarding infant feeding practices in women who are HIV negative or HIV positive but undiagnosed are based on the results of the 1998 Demographic and Health Survey.\textsuperscript{16} About 87% of these women are assumed to start breastfeeding, and the duration of breastfeeding is modeled using a Weibull distribution with a median of 18 months and a shape parameter of 2. All these women are assumed to practice mixed feeding because exclusive breastfeeding (EBF) was rare before the introduction of PMTCT programs.\textsuperscript{16,34} Women who were HIV positive at delivery and who practice mixed feeding are assumed to have a fixed monthly probability of transmitting HIV, \( h_1 \). Breastfeeding HIV-negative mothers are assumed to acquire HIV at the same rate as pregnant women, and for an average period of 3 months after acquiring HIV, are assumed to have a higher monthly probability of transmitting HIV through mixed feeding, \( h_0 \). The parameter \( h_0 \) is estimated from studies of the cumulative HIV transmission risk from breastfeeding mothers who have seroconverted (summarized in Table 1), by noting that this cumulative risk can be expressed as

\[
\int_0^\infty \exp \left( -x \left( \frac{1}{3} + \frac{1}{\mu} \right) \right) (1 - h_0)^x \left( -\ln \left( 1 - h_0 \right) \right) dx
\]

where \( \mu \) is the average duration of breastfeeding after seroconversion. Setting \( \mu = 9 \) months (half of the average duration in the 2 largest studies\textsuperscript{30,31} and setting \( h_0 = 0.16 \) gives a cumulative transmission risk of 0.28, consistent with the pooled estimate of 0.27 in Table 1.

In each year, a proportion of pregnant women are assumed to receive HIV testing, increasing from 3% in 2000 to 92% in 2010 and subsequent years (see Section 1, Supplemental Digital Content 1, http://links.lww.com/QAI/A241). A fraction of those women testing positive start antiretroviral treatment (ART) if their CD4 count is below 200 (or below 350 following the change in South African guidelines in 2010\textsuperscript{35}). Of the remaining women who are diagnosed HIV positive, a fraction is assumed to receive single-dose nevirapine, and following changes in guidelines in 2008,\textsuperscript{36} a fraction of women receiving single-dose nevirapine are assumed also to receive short-course zidovudine. Of the women who are diagnosed HIV positive antenatally, 50% are assumed to avoid breastfeeding completely,\textsuperscript{37,38} 35% practice EBF, and 15% practice mixed feeding.\textsuperscript{39} The monthly probability of postnatal transmission is reduced if the child receives extended nevirapine prophylaxis, if the mother receives ART or if the mother practices EBF. HIV-diagnosed women who practice mixed feeding are assumed to do so for a median of 7 months. HIV-diagnosed women who practice EBF are assumed to do so for a median of 2 months (up to a maximum of 6 months), after which 30% are assumed to discontinue breastfeeding completely and the remainder practice mixed feeding (ie, continue breastfeeding while introducing complementary feeds), for a median of 7 months.\textsuperscript{39–41} Following the change in guidelines in 2010,\textsuperscript{35} a proportion of HIV-diagnosed women who choose to breastfeed are assumed to administer extended nevirapine prophylaxis to their children, with this proportion rising to 80% by 2013. Following the more recent announcement of a phasing out of free provision of formula milk in public clinics, the proportion of HIV-diagnosed women who avoid breastfeeding is assumed to

\textsuperscript{[41x677]}
FIGURE 1. Multistate model of mother-to-child transmission. ART, antiretroviral treatment (long-term treatment for mother’s health); ARV, antiretroviral; AZT, zidovudine; EBF, exclusive breastfeeding; MF, mixed feeding; sd NVP, single-dose nevirapine
Shaded cells represent states in which mothers may administer extended nevirapine prophylaxis to their children. Solid gray lines represent discontinuation (or avoidance) of breastfeeding by mothers of uninfected children, dotted gray lines represent postnatal transmission, and dashed gray lines represent mother-to-child transmission at or before delivery. In the default scenario, there is no retesting of mothers, either during late pregnancy or at 6-week immunization visits. However, the model does allow for retesting at 34-week gestation, and the model allows for undiagnosed HIV-positive mothers to be diagnosed if screening is conducted at 6-week immunization (*). If women who seroconvert between their first antenatal visit and delivery are diagnosed, it is assumed they may receive short-course ARV prophylaxis, but that they would not be eligible to start ART before delivery. Rates at which women discontinue breastfeeding depend on the age of the child and the mother’s knowledge of her HIV status.
decline from 50% in 2010 to 20% in 2013. Assumptions about vertical transmission rates and the efficacy of PMTCT are summarized in Table 2, and a more detailed description of the model is provided in Supplemental Digital Content 1 (http://links.lww.com/QAI/A241).

Children who acquire HIV are assumed to progress to a state of ART eligibility, after which they may start ART. Rates of progression to ART eligibility and rates of AIDS mortality in ART-eligible children are assumed to depend on age and mode of transmission (perinatal or postnatal), as described elsewhere. Numbers of new infections in children and numbers of children in different exposed and infected states are calculated at monthly time steps, starting in 1985. To ensure that the model assumptions regarding mother-to-child transmission (MTCT) and pediatric HIV survival are plausible, the model is fitted to age-specific pediatric HIV prevalence data from national household surveys conducted in 2005 and 2008, using a Bayesian uncertainty analysis approach. Beta prior distributions are specified to represent ranges of uncertainty around key parameters, and the means and standard deviations of these distributions are included in Table 2. Posterior distributions, representing the ranges of model results consistent with both the observed pediatric HIV prevalence data and the ranges of uncertainty around the input parameters, were simulated numerically using Incremental Mixture Importance Sampling.

Three possible interventions are considered to reduce vertical transmission from mothers who acquire HIV after their first antenatal visit:

1. Maternal HIV incidence is assumed to reduce by 50% after 2010. A 50% reduction in HIV incidence by 2011 is a target of South Africa’s National Strategic Plan, and could potentially be achieved in pregnant and breastfeeding women through intensified condom promotion, partner outreach, microbicides, and preexposure prophylaxis.

2. The offer of antenatal screening is assumed to be repeated at 34-week gestation in women who tested negative or did not receive testing at their first antenatal visit, from 2010 onward. This has been recommended in recent PMTCT guidelines, but implementation has been limited. It is assumed that 80% of women who previously tested negative would accept the offer of retesting, and 50% of women who did not receive testing at their first antenatal visit get tested at 34 weeks.

3. Mothers and infants are assumed to be screened for HIV at 6-week immunization visits, from 2010 onward. Although not part of current South African guidelines, this has been proposed by Rollins et al. About 92% of mothers are assumed to attend 6-week immunization visits, and 66% of women testing positive are assumed to receive their test results. Of those women who are diagnosed HIV positive, 50% are assumed to discontinue breastfeeding immediately (this proportion reducing to 20% by 2013), and those who continue to breastfeed are assumed to do so for a shorter period (median 7 months), with 80% administering nevirapine prophylaxis to their infants.

For ease of reference, we use the term ‘recently infected mothers’ to refer to women who seroconvert after their first antenatal visit, either during late pregnancy or while breastfeeding.

RESULTS

Age-specific model estimates of HIV prevalence were reasonably consistent with survey estimates, although the model tended to estimate higher HIV prevalence in 2008 than observed in the 2008 survey, possibly a reflection of the high rates of test refusal in children. Posterior distributions for the MTCT parameters in Table 2 were similar to the prior distributions, except in the case of the probability of MTCT from chronically infected mothers, per year of mixed feeding [posterior mean of 11.6%, 95% confidence interval (CI): 8.4% to 15.7%].

The model estimates that the number of new HIV infections in South African children reached its highest level in 2002, at 94,000 per annum (95% CI: 86,000 to 104,000), and dropped to 57,000 per annum (95% CI: 51,000 to 64,000) by 2008. This incidence is 44% lower (95% CI: 39% to 47%) than the level of pediatric HIV incidence that would have been expected over the same period in the absence of PMTCT (Fig. 2A). The number of new HIV infections in children is projected to drop to 39,000 per annum (95% CI: 34,000 to 43,000) by 2014, after the implementation of the revised 2010 PMTCT guidelines (but not allowing for the additional interventions to reduce transmission from recently infected mothers). This represents a 60% reduction (95% CI: 57% to 63%) in pediatric HIV incidence, relative to what would be expected in the absence of PMTCT.

In 1990, when antenatal HIV prevalence was <1% but HIV incidence was increasing rapidly, an estimated 60% of vertical transmission (95% CI: 55% to 64%) was from mothers who acquired HIV after their first antenatal visit (Fig. 2B). As HIV prevalence in pregnant women increased relative to HIV incidence, the proportion of vertical transmission from recently infected mothers declined, and would have continued to decline in the absence of PMTCT, to a level of 15% (95% CI: 13% to 17%) by 2008 (15,000 of 102,000 infections). However, PMTCT programs have significantly reduced transmission from mothers who were seropositive at their first antenatal visit, while having negligible impact on transmission from recently infected mothers. As a result, the proportion of vertical transmission from recently infected mothers has increased since 2002, rising to 26% (95% CI: 22% to 30%) in 2008 (15,000 of 57,000 infections). The proportion is projected to increase to 34% (95% CI: 29% to 39%) by 2014 (13,000 of 39,000 infections), in the absence of specific interventions to prevent transmission from recently infected mothers.

At all stages in the epidemic, most of the vertical transmission from mothers who have acquired HIV after their first antenatal visit is postnatal transmission (Fig. 3A) because there is more opportunity for maternal seroconversion during the long breastfeeding period than during the relatively short period between first antenatal visit and delivery. This is in contrast to transmission from mothers who are HIV positive.
at their first antenatal visit, which is predominantly perinatal. Because postnatally infected children are assumed to survive for longer than perinatally infected children, they account for a greater proportion of prevalent HIV (Fig. 3B) than incident HIV (Fig. 3A). The proportion of prevalent HIV in children that is attributable to transmission from recently infected mothers was 30% in 2010 (95% CI: 26% to 35%). This proportion varies substantially by age, from 18% (95% CI: 13% to 22%) in infants to 58% (95% CI: 52% to 65%) in 14-year-olds, in 2010 (Fig. 3D). In 2000, when the epidemic was less mature, fewer HIV infections occurred in older children, but age-specific proportions of pediatric HIV acquired from recently infected mothers were higher (Fig. 3C).

Reducing HIV incidence in pregnant and breastfeeding women by 50% would reduce the number of new HIV infections in children, over the 2010–2015 period, by 16.2% (95% CI: 13.9% to 18.6%). Repeating the offer of HIV testing in late pregnancy would reduce the number of new HIV infections in children by 11.2% (95% CI: 9.5% to 12.7%), and conducting HIV screening in mothers and infants at 6-week immunization visits would reduce new infections in children by 3.5% (95% CI: 2.7% to 4.4%). However, the numbers of HIV infections averted per 1000 HIV tests performed in late pregnancy (7.2, 95% CI: 6.4 to 8.1) and at immunization clinics (1.9, 95% CI: 1.4 to 2.6) are substantially lower than the number of HIV infections averted per test performed at the first antenatal visit (62.5, 95% CI: 55.7 to 70.7), and additional screening after the first antenatal visit would therefore be less cost-effective. If all 3 interventions were introduced together, the average annual number of new pediatric HIV infections over the 2010–2015 period would reduce from 38,000 to 27,000, a reduction of 28% (95% CI: 25% to 31%). Combined with existing PMTCT interventions, this would represent a reduction in the annual number of new HIV infections of 72% (95% CI: 68% to 74%) in 2014, relative to what would be expected in the absence of PMTCT.

**DISCUSSION**

These results suggest that mothers who experience HIV seroconversion during pregnancy and breastfeeding contribute substantially to vertical transmission of HIV. The relative significance of this transmission depends on 3 factors. First, the contribution is substantially higher during early-stage HIV epidemics, in which HIV incidence rates are high and HIV prevalence rates are still relatively low; the contribution can be expected to decline as antenatal HIV prevalence rises and adult HIV incidence starts to decline. Second, the relative contribution is higher the greater the extent of PMTCT programs, which have been directed almost exclusively at women who are seropositive at their first antenatal visit. Third, the model simulations suggest that the contribution to postnatal transmission is substantially greater than the contribution to perinatal transmission, and the significance of transmission from mothers who seroconvert after their antenatal screening visit is therefore likely to depend on the average duration of breastfeeding. The median duration of lactation in South Africa is shorter than in most other African countries, and the proportion of vertical transmission from mothers who are recently infected could therefore be higher in other African countries. However, access to PMTCT in other African countries is generally more limited than in South Africa, which would imply a lower proportion of vertical transmission from mothers who seroconvert during pregnancy and breastfeeding.

This analysis suggests that “virtual elimination” of mother-to-child transmission of HIV is likely to be challenging, even with optimistic assumptions about the future introduction of interventions to prevent transmission from pregnant women who are initially seronegative. Repeated HIV screening in late pregnancy would have some effect on the identification of recently infected women, but most of the modeled benefit of this strategy is because of the diagnosis of chronically infected women who previously refused testing (see Section 4, Supplemental Digital Content 1, http://links.lww.com/QAI/A241).

The benefits of HIV screening at immunization clinics, if they were introduced in South Africa, would probably be modest, amounting to a less than 5% reduction in current pediatric HIV incidence. The most effective way to limit transmission from seroconverting mothers is to prevent them from acquiring HIV in the first place, but there is uncertainty regarding the ideal means to achieve this. HIV counseling and testing has generally had negligible impact on behavior in individuals who test HIV negative, and it is therefore debatable whether condom promotion to HIV-negative pregnant women would substantially reduce HIV incidence. HIV counseling and...
testing of male partners has been suggested as one strategy for limiting maternal HIV incidence, but African studies that have attempted to integrate male partners into antenatal HIV testing have typically managed to test only 10%–20% of partners. Promising recent evidence suggests that tenofovir-based products could provide protection against maternal HIV acquisition, but there is currently a lack of evidence regarding the safety of tenofovir use during pregnancy and lactation.

A limitation of this analysis is that maternal HIV incidence rates have been estimated from the ASSA2003 model, which calculates HIV incidence in pregnant women as a weighted average of age-specific female incidence rates, where weights are numbers of births to HIV-negative women at each age. This does not allow for the possibility that pregnant women may be biologically or behaviorally different from other women at the same age. Some evidence suggests that women may experience heightened susceptibility to HIV during pregnancy and during the early postpartum period, although other studies have not confirmed this. If the actual maternal HIV incidence rates during pregnancy and breastfeeding are higher than estimated by the ASSA2003 model, our model is likely to underestimate the extent of vertical transmission from mothers who seroconvert during pregnancy and breastfeeding. However, it is also possible that the ASSA2003 model may underestimate the extent of vertical transmission from mothers who seroconvert during pregnancy and breastfeeding. However, it is also possible that the ASSA2003 model may underestimate the extent of recent reductions in maternal HIV incidence because of inadequate allowance for recent increases in condom usage and HIV testing. A more general limitation is the lack of information regarding several key MTCT parameters. It is possible that the ASSA2003 model may underestimate the extent of recent reductions in maternal HIV incidence because of inadequate allowance for recent increases in condom usage and HIV testing. In a sensitivity analysis to explore the effect of either halving or doubling the rate of maternal HIV incidence in 2008, the proportion of mother-to-child transmission from recently infected mothers changed to 15.4% (95% CI: 13.0% to 17.9%) and 39.8% (95% CI: 35.2% to 44.8%), respectively (see Section 6, Supplemental Digital Content 1, http://links.lww.com/QAI/A241).

A more general limitation is the lack of information regarding several key MTCT parameters. It is possible that feeding practices of HIV-negative and undiagnosed HIV-positive mothers may have changed since the time of the 1998 Demographic and Health Survey, but there is little evidence to show this. There is also little information on feeding practices in women who have been diagnosed HIV positive.

### TABLE 2. Mother-to-Child Transmission Assumptions

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean Value (%)</th>
<th>SD (%)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage of pregnant HIV-positive women with</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4 &gt; 500</td>
<td>36.6</td>
<td></td>
<td>Meta-analysis of published studies^42</td>
</tr>
<tr>
<td>CD4 350–500</td>
<td>24.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4 200–349</td>
<td>24.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4 &lt; 200</td>
<td>14.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transmission rate at/before birth, from chronically infected women with no ARV prophylaxis with</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4 &gt;500</td>
<td>13.4</td>
<td></td>
<td>Meta-analysis of published studies^42</td>
</tr>
<tr>
<td>CD4 350–500</td>
<td>15.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4 200–349</td>
<td>25.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4 &lt; 200</td>
<td>35.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transmission rate at/before birth, from acutely infected women with no ARV prophylaxis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percentage of HIV-diagnosed women who receive single-dose nevirapine, if not starting ART</td>
<td>75.0</td>
<td>10.0</td>
<td>Stringer et al,^41 Sherman et al,^44 Nkonki et al^37</td>
</tr>
<tr>
<td>Percentage reduction in perinatal MTCT if the mother receives single-dose nevirapine</td>
<td>40.0</td>
<td></td>
<td>Leroy et al^46</td>
</tr>
<tr>
<td>Percentage reduction in perinatal MTCT if mother receives short-course zidovudine</td>
<td>65.0</td>
<td></td>
<td>Sperling et al^1</td>
</tr>
<tr>
<td>Percentage reduction in perinatal MTCT if mother receives single-dose nevirapine + short-course zidovudine</td>
<td>80.0</td>
<td></td>
<td>Dabis et al,^47 Lallemant et al^48</td>
</tr>
<tr>
<td>Transmission rate at/before birth, from chronically infected women starting long-term ART</td>
<td>2.0</td>
<td></td>
<td>Tonwe-Gold et al,^49 Peltier et al.^50</td>
</tr>
<tr>
<td>Probability of MTCT from chronically infected mothers, per year of mixed feeding</td>
<td>14.0</td>
<td>2.5</td>
<td>Meta-analysis,^53 adjusted to reflect the effect of excluding EBF</td>
</tr>
<tr>
<td>Probability of MTCT from acutely infected mothers, per month of mixed feeding</td>
<td>16.0</td>
<td>3.0</td>
<td>Derived from Table 1 using equation 1</td>
</tr>
<tr>
<td>Ratio of postnatal transmission risk per month of EBF to postnatal transmission risk per month of mixed feeding</td>
<td>50.0</td>
<td>15.0</td>
<td>Coovadia et al,^54 Becquet et al^55</td>
</tr>
<tr>
<td>Percentage reduction in monthly postnatal MTCT risk if the child receives extended nevirapine prophylaxis</td>
<td>60.0</td>
<td></td>
<td>Kumwenda et al,^56 Chasela et al,^57 SWEN Study Team^58</td>
</tr>
<tr>
<td>Percentage reduction in monthly postnatal MTCT risk if the mother receives long-term ART</td>
<td>80.0</td>
<td></td>
<td>Taha et al^57</td>
</tr>
</tbody>
</table>

^SDs (standard deviations) are shown only for those parameters that are included in the uncertainty analysis.
and counseled on infant feeding. Since the introduction of the new PMTCT guidelines in 2008 and 2010, there has been little data on the extent to which the changes recommended in these guidelines have been implemented, and the model projections beyond 2008 therefore need to be treated with caution. A recent South African survey found that perinatal HIV transmission rates by 6 weeks were reduced to 3.5% by 2010, and this implies a higher level of PMTCT coverage than assumed in our model. Since higher PMTCT coverage implies proportionately greater contributions to vertical transmission from recently infected mothers, our model may therefore underestimate the proportion of vertical transmission in 2010 that was from recently infected mothers. There is also uncertainty regarding the extent to which HIV prevalence data and PMTCT data collected from women attending public antenatal clinics can be generalized to the whole population of pregnant women, some of whom seek private antenatal care or do not seek antenatal care at all. However, the proportion of pregnant women who access public sector antenatal care in South Africa is around 82%, and any bias associated with the exclusion of other women is therefore likely to be small. As efforts to eliminate vertical transmission intensify, it will become increasingly important to focus on transmission from recently infected mothers. Projections that do not take this transmission into account are likely to underestimate pediatric HIV incidence and prevalence substantially, with implications for the estimation of pediatric ART need and AIDS mortality. Policymakers will need to seek creative solutions to this
problem and will need to move toward greater integration of adult and pediatric HIV prevention if this challenge is to be addressed effectively.

ACKNOWLEDGMENTS

L. Johnson thanks the South African Medical Research Council and the William and Flora Hewlett Foundation for funding.

REFERENCES

2. Farquhar C, Mbori-Ngacha D, Overbaugh J, et al. Illness during pregnancy and bacterial vaginosis are associated with in-uterus HIV-1 transmis-
4. Rousseau CM, Ndaiwi RW, Richardson BA, et al. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmis-
1
8. Koppman JS, Jacque JA, Welch GW, et al. The role of early HIV infec-
9. Hyman JM, Li J, Stanley EA. The differential infectivity and staged pro-
15. Rudin C, Lauper U, Biedermann K. HIV seroconversion during preg-
nancy [Abstract W.C.3247]. Presented at: 7th International AIDS Conf-
ference; June 16–21, 1991; Florence, Italy.
20. Embree NE, NJenga S, Datta P, et al. Risk factors for postnatal mother-
24. Roogangiputhipong A, Sirivasin W, Simonds RJ, et al. HIV seroconver-
27. Humphrey JH, Marinda E, Mutasa K, et al. Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: pro-
spective cohort study. BMJ. 2010;341:c5980.
31. Wittert GA, Weller D. Breastfeeding and postnatal mother-to-child trans-
38. Coutsoudis A, Pillay K, Kuhn L, et al. Method of feeding and transmis-


